Table 1.

IC50 values of PC3, PC3-TxR, DU145, and DU145-TxR cellsa

DrugPC3PC3-TxRFold resistancebDU145DU145-TxRFold resistanceb
Paclitaxel (nmol/L)6.14 ± 0.91941 ± 731534.88 ± 0.472,438 ± 309500
Docetaxel (nmol/L)3.56 ± 0.36383 ± 541082.71 ± 0.25912 ± 95337
Cabazitaxel (nmol/L)1.19 ± 0.1314.8 ± 1.1120.79 ± 0.2930.4 ± 2.839
Orlistat (μmol/L)30 ± 5.320 ± 6.10.6746 ± 7.742 ± 9.50.92
NanoOrl (μmol/L)37 ± 8.616 ± 2.60.4351 ± 6.639 ± 3.70.77
  • aCells were treated for 72 hours, and cell viability was assessed with the CCK-8 assay (Dojindo). Table shows the mean IC50 ± SD of at least two independent experiments.

  • bFold resistance is the ratio of the IC50 value in TxR cells relative to parental cells for the same drug. “NanoOrl (μmol/L)” represents the equivalent concentration of orlistat and not the concentration of the nanoparticles.